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graBACKGROUND Intensive low-density lipoprotein cholesterol therapy with ezetimibe/simvastatin in IMPROVE-IT
(IMProved Reduction of Outcomes: Vytorin Efﬁcacy International Trial) signiﬁcantly reduced the ﬁrst primary endpoint
(PEP) in patients post-acute coronary syndrome (ACS) compared to placebo/simvastatin.
OBJECTIVES This analysis tested the hypothesis that total events, including those beyond the ﬁrst event, would also
be reduced with ezetimibe/simvastatin therapy.
METHODS All PEP events (cardiovascular [CV] death, myocardial infarction [MI], stroke, unstable angina [UA] leading
to hospitalization, coronary revascularization $30 days post-randomization) during a median 6-year follow-up were
analyzed in patients randomized to receive ezetimibe/simvastatin or placebo/simvastatin in IMPROVE-IT. Negative
binomial regression was used for the primary analysis.
RESULTS Among 18,144 patients, there were 9,545 total PEP events (56% were ﬁrst events and 44% subsequent
events). Total PEP events were signiﬁcantly reduced by 9% with ezetimibe/simvastatin vs placebo/simvastatin (inci-
dence-rate ratio [RR]: 0.91; 95% conﬁdence interval [CI]: 0.85 to 0.97; p ¼ 0.007), as were the 3 pre-speciﬁed sec-
ondary composite endpoints and the exploratory composite endpoint of CV death, MI, or stroke (RR: 0.88; 95% CI: 0.81
to 0.96; p ¼ 0.002). The reduction in total events was driven by decreases in total nonfatal MI (RR: 0.87; 95% CI: 0.79
to 0.96; p ¼ 0.004) and total NF stroke (RR: 0.77; 95% CI: 0.65 to 0.93; p ¼ 0.005).
CONCLUSIONS Lipid-lowering therapy with ezetimibe plus simvastatin improved clinical outcomes. Reductions in total
PEP events, driven by reductions in MI and stroke, more than doubled the number of events prevented compared with
examining only the ﬁrst event. These data support continuation of intensive combination lipid-lowering therapy after an
initial CV event. (IMProved Reduction of Outcomes: Vytorin Efﬁcacy International Trial [IMPROVE-IT]; NCT00202878)
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354M ost long-term acute coronarysyndrome (ACS) trials use sur-vival analysis methods that take
into account only the ﬁrst event that a pa-
tient experiences during the trial to evaluate
efﬁcacy, even if the primary endpoint (PEP)
is a composite made up of multiple compo-
nent events. This is a somewhat limited eval-
uation of efﬁcacy, as subjects with a nonfatal
event continue to be followed during the
trial, and can experience additional events
during the course of follow-up. In clinical
practice, a ﬁrst event usually does not reﬂect
the complete cardiovascular clinical experi-
ence of a patient over time. Indeed, previous
trials have examined total events forcomparing high-intensity versus moderate-intensity
statins. In both the PROVE IT-TIMI 22 (Pravastatin
or Atorvastatin Evaluation and Infection Therapy-
Thrombolysis In Myocardial Infarction 22) and the
IDEAL (Incremental Decrease in End Points Through
Aggressive Lipid Lowering) trials, analyses demon-
strated that lower low-density lipoprotein cholesterol
(LDL-C) achieved with high-intensity statins reduced
both the ﬁrst cardiovascular event as well as the total
number of cardiovascular events post-ACS compared
with moderate-intensity statins (1,2).SEE PAGE 362As previously reported (3), IMPROVE-IT (IMProved
Reduction of Outcomes: Vytorin Efﬁcacy Interna-
tional Trial) showed an overall reduction in the
primary composite endpoint of time to ﬁrst cardio-
vascular (CV) death, nonfatal MI, unstable angina
requiring hospitalization, coronary revascularization
($30 days post-randomization), or nonfatal stroke
over a median 6 years of follow-up with the combi-
nation therapy of simvastatin and ezetimibe (a non-
statin lipid-lowering agent) compared to simvastatin
and placebo in patients with recent ACS and LDL-C of
50 to 125 mg/dl. We tested the pre-speciﬁed hypoth-
esis in IMPROVE-IT that, in addition to reducing ﬁrstrs Squibb, CSL Behring, Essentialis, Kowa, Lipimedix, Pﬁzer, Rege
ng the conduct of the study; and has received personal fees from
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received August 20, 2015; revised manuscript received Octoberevents in patients after an ACS, combination therapy
with ezetimibe plus simvastatin would also reduce
total events compared with simvastatin alone.
METHODS
The study design and primary results of IMPROVE-IT
have been published previously (3–6). Patients who
were $50 years of age were eligible for inclusion
if they were hospitalized for an ACS within the
preceding 10 days, with either acute myocardial
infarction (MI) with or without electrocardiographic
ST-segment elevation, or high-risk unstable angina
(UA). Eligible patients had an LDL-C concentration of
$50 mg/dl (1.3 mM/l), with a maximum of 125 mg/dl
(3.2 mM/l) if not receiving chronic lipid-lowering
therapy, or #100 mg/dl (2.6 mM/l) if chronically
treated. A total of 18,144 patients were randomized in
a double-blind manner to either placebo plus simva-
statin, 40 mg, or the combination of ezetimibe,
10 mg, plus simvastatin, 40 mg once daily, in addition
to standard ACS therapy. Simvastatin dose was
increased in each group to 80 mg if LDL-C was
>79 mg/dl (2.0 mM/l).
Patients had follow-up visits at 30 days, 4 months,
and every 4 months thereafter. The primary com-
posite endpoint was time to ﬁrst CV death, nonfatal
MI, UA requiring hospitalization, coronary revascu-
larization ($30 days post-randomization), or nonfatal
stroke. Study medication and follow-up were to be
continued until trial end even if a patient experienced
a nonfatal component of the PEP. All endpoints
(excluding revascularization) used in the analyses in
the initial as well as this report were adjudicated by
members of an independent clinical events commit-
tee who were blinded to the treatment assignment.
STATISTICAL ANALYSIS. Baseline clinical character-
istics are presented as frequencies for catego-
rical variables and medians and interquartile ranges
for continuous variables. Comparisons between
baseline characteristics for patients with no
events, a single event, or multiple events, as well asneron, and Sanoﬁ. Dr. Blazing received support from
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355for the comparison of ezetimibe/simvastatin with
placebo/simvastatin in the cohort of patients with at
least 1 event (Online Table 1), were made using the
chi-square test for categorical variables and Wilcoxon
rank test for continuous variables. Negative binomial
regression analysis, a type of modiﬁed Poisson model,
was performed to compare the total number of PEPs
and other endpoints between all patients in the eze-
timibe/simvastatin and placebo/simvastatin groups.
This model included an exposure variable for dura-
tion of follow-up as this could vary by subject.
Incidence-rate ratio (RR) and corresponding 95%
conﬁdence intervals (CI) are reported from the nega-
tive binomial regression model. In addition, we per-
formed a pre-speciﬁed analysis using the Wei, Lin,
and Weissfeld (WLW) method (7), which is a marginal
model and an extension of survival models based on
the Cox proportional hazard; the ﬁrst 4 events that
could have occurred in a subject were evaluated in
the model. An additional sensitivity analysis was
performed using a Prentice, Williams, and Peterson
(PWP) model (8), which is a conditional model and
also an extension of survival models based on the Cox
proportional hazard. An Andersen Gill model was also
performed as a sensitivity analysis using up to the
ﬁrst 4 events in a subject.
Efﬁcacy comparisons were performed according to
the intention-to-treat principle. All tests were 2-sided
with a p value <0.05 considered to be signiﬁcant.
Analyses were performed using Stata/IC version 13.1
software (College Station, Texas) and SAS version 9.3
software (Cary, North Carolina).
RESULTS
The median length of follow-up was 6 years (25th,
75th percentiles: 4.3 and 7.1 years). Compared to pa-
tients with only 1 event, patients with multiple events
had more comorbidities at study entry, including
hypertension and diabetes; were more often on prior
statin therapy; and more frequently had previously
experienced MI, angina, and revascularization
(Table 1). The 1-month LDL-C levels were lowest in
those without a subsequent PEP event and highest in
those with more than 1 PEP event (mean 58.3 mg/dl if
no event vs. 59.6 mg/dl if 1 event and 60.1 mg/dl if
>1 event, p <0.001 for 3-way comparison). However,
there were no further differences when LDL-C levels
in subjects with 1 PEP event were compared with
those who had >1 PEP event (p ¼ 0.54). The frequency
of reaching a target of LDL-C concentration of
<70 mg/dl at 1 month was also analyzed. An LDL-C of
<70 mg/dl at 1 month was most common among
subjects without a PEP event during the trial (74.2%)compared with subjects with 1 event (71.0%) or
>1 event (69.0%; p < 0.001 for 3-way comparison),
but again, there was no statistically signiﬁcant dif-
ference when we compared subjects with 1 PEP
event with those who had >1 PEP event (p ¼ 0.16).
Baseline characteristics among patients who ex-
perienced at least 1 event were similar for those
randomized to ezetimibe/simvastatin compared to
those randomized to placebo/simvastatin (Online
Table 1).
EVENTS. During the course of the trial, a total of
9,545 PEP events occurred. Of these, 5,314 (56%) were
ﬁrst events, which were included in the primary
IMPROVE-IT study analysis (3), and there were an
additional 4,231 (44%) events that occurred after the
ﬁrst PEP event during the course of the trial, and were
thus not included in the primary analysis. Overall, a
similar proportion of ﬁrst and additional events were
stroke, UA, and CV death (Figure 1). In contrast, there
were proportionately fewer MIs (24.0% vs. 31.7%) and
proportionately more revascularizations (58.4% vs.
43.8%) among the additional events compared to
the distribution of ﬁrst events. There were a total of
48 peri-percutaneous coronary intervention (PCI) MI
events, of which only 4 were the ﬁrst PEP event
that occurred in a subject; no subject had more than
1 peri-PCI MI during the trial.
When we considered the total number of events of
the 18,144 subjects, 70.7% (n ¼ 12,830) had no events,
16.6% (n ¼ 3,017) had a single event, 7.3% (n ¼ 1,325)
had 2 PEP events, and 5.4% (n ¼ 972) had 3 or more
such events (Online Table 2). The maximum number
of events experienced was 14 events each in 2
patients.
EFFICACY. As previously reported (3), the PEP of ﬁrst
occurrence of CV death, nonfatal MI, UA requiring
hospitalization, coronary revascularization, or
nonfatal stroke was signiﬁcantly reduced by 170
events in the ezetimibe/simvastatin group compared
with the placebo/simvastatin group (7-year
Kaplan-Meier rate ¼ 32.7% [n ¼ 2,572] vs. 34.7%,
respectively [n ¼ 2,742]; hazard ratio [HR]: 0.936;
95% CI: 0.887 to 0.988; p ¼ 0.016). In addition to this
reduction in ﬁrst primary events, there were 251
fewer subsequent events in the ezetimibe/simvasta-
tin group (n ¼ 1,990 in the ezetimibe/simvastatin
group vs. n ¼ 2,241 in the placebo/simvastatin group)
(Central Illustration, Online Table 3), resulting in 421
fewer total primary events during follow-up (total
events n ¼ 4,562 vs. n ¼ 4,983, respectively; RR: 0.91;
95% CI: 0.85 to 0.97; p ¼ 0.007). When comparing
ezetimibe/simvastatin versus placebo/simvastatin,
there was a 13% reduction in the total number of MIs
TABLE 1 Baseline Characteristics in Patients With No Events, a Single Event, or Multiple Events*
No Events
(n ¼ 12,830)
1 Event
(n ¼ 3,017)
Multiple Events
(n ¼ 2,297)
p Value for
1 vs. $2 Events
Male 75.1 76.4 78.1 0.162
Caucasian 83.3 84.5 86.2 0.070
Age, yrs 62 (56–70) 64 (58–73) 64 (57–72) 0.006
LDL-C >95 mg/dl (median) at qualifying event 51.0 47.0 42.6 0.001
Qualifying event 0.173
STEMI 27.7 27.8 26.2
NSTEACS 72.3 72.2 73.8
Prior MI 18.1 25.7 31.4 <0.001
History of angina 37.5 46.9 53.5 <0.001
History of diabetes 24.6 31.9 35.3 0.009
History of hypertension 59.1 65.7 68.7 0.024
Current smoker 33.5 31.4 32.3 0.489
History of CHF 3.4 6.6 6.6 0.972
History of PAD 4.5 7.7 8.7 0.164
History of cerebrovascular disease 6.0 9.2 9.7 0.549
Family history of coronary artery disease 27.4 28.7 30.2 0.239
Prior CABG 7.1 12.0 18.1 <0.001
History of PCI 16.3 24.0 32.5 <0.001
Catheterization for qualifying event 88.4 85.5 87.5 0.035
PCI for treatment of qualifying event 70.0 68.0 73.4 <0.001
BMI group, kg/m2 0.023
BMI #25 26.8 25.9 24.9
BMI >25 to 30 43.5 43.4 40.8
BMI >30 29.8 30.7 34.2
Creatinine clearance group at qualifying event, ml/min 0.158
CrCl <60 16.6 22.2 21.5
CrCl 60 to <90 39.2 39.6 37.7
CrCl $90 44.2 38.2 40.8
Medications prior to qualifying event
Aspirin 38.6 48.6 54.2 <0.001
Beta-blocker 31.5 40.2 45.7 <0.001
Statin 31.2 39.5 46.0 <0.001
Thienopyridine 9.0 13.1 17.9 <0.001
Values are % or median (interquartile range). *Pooled randomization groups. For 3-way comparison, all p < 0.001 except sex (p ¼ 0.005), qualifying event (p ¼ 0.289), current
smoker (p ¼ 0.076), and family history CAD (p ¼ 0.017).
BMI ¼ body mass index; CABG ¼ coronary artery bypass graft; CHF ¼ congestive heart failure; CrCl ¼ creatinine clearance; LDL ¼ low-density lipoprotein; MI ¼ myocardial
infarction; NSTEACS ¼ non-ST-segment elevation acute coronary syndrome; PAD ¼ peripheral artery disease; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment
elevation myocardial infarction.
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356(RR: 0.87; 95% CI: 0.79 to 0.96; p ¼ 0.004), a 23%
reduction in the total number of strokes (RR: 0.77; 95%
CI: 0.65 to 0.93; p ¼ 0.005), and a nonsigniﬁcant 6%
reduction in coronary revascularizations (RR: 0.94;
95% CI: 0.88 to 1.01; p ¼ 0.095) (Figure 2). Among the
total 48 peri-PCI MI events, 20 occurred in the ezeti-
mibe/simvastatin group, and 28 occurred in the pla-
cebo/simvastatin group. Among the stroke events,
total ischemic stroke was reduced with ezetimibe/
simvastatin (RR: 0.76; 95% CI: 0.63-0.91; p ¼ 0.002).
Recurrent hemorrhagic strokes were uncommon, with
only 5 subjects having an additional hemorrhagic
stroke (3 subjects in the placebo/simvastatin group and
2 subjects in the ezetimibe/simvastatin group), and no
difference was observed between randomized groupsin total hemorrhagic stroke (RR: 1.32; 95% CI: 0.86 to
2.03; p¼ 0.20). Total urgent revascularization was also
reduced with ezetimibe/simvastatin (RR: 0.79; 95% CI:
0.70 to 0.90; p <0.001). The number of total unstable
angina events was similar between treatment groups,
as was the number of CV deaths.
Total events were also consistently lower in the
ezetimibe/simvastatin group for the 3 pre-speciﬁed
secondary endpoints (Figure 3), as well as for the
exploratory endpoint of CV death, MI, or stroke
(RR: 0.88; 95% CI: 0.81 to 0.96; p ¼ 0.002).
In the WLW Cox model of the PEP, results were
similar, with a reduction in primary endpoint events
associated with the ezetimibe/simvastatin group
(HR: 0.93; 95% CI: 0.89 to 0.99; p ¼ 0.01) (Figure 4).
CENTRAL ILLUSTRATION First, Additional, and Total Primary Endpoint Events During Follow-Up by
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The ﬁrst occurrence of the primary endpoint was signiﬁcantly reduced in the ezetimibe/simvastatin group compared to that in the placebo/
simvastatin group (HR: 0.936; 95% CI: 0.887 to 0.988; p ¼ 0.016), as were additional events (RR: 0.88; 95% CI: 0.79 to 0.98) and total
events (RR: 0.91; 95% CI: 0.85 to 0.97; p ¼ 0.007).
FIGURE 1 Number of First and Subsequent Primary Endpoint Events, Overall and by Component
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Overall, a similar proportion of ﬁrst and additional events were stroke (7.8% vs. 5.0%, respectively), unstable angina (4.2% vs. 2.8%,
respectively), and cardiovascular death (12.4% vs. 9.8%, respectively). There were proportionately fewer MIs (24.0% vs. 31.7%, respectively)
and proportionately more revascularizations (58.4% vs. 43.8%, respectively) among the additional events than among the ﬁrst events. CVD ¼
cardiovascular death; Revasc ¼ revascularization; MI ¼ myocardial infarction; NF ¼ nonfatal; UA ¼ unstable angina.
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FIGURE 3 Total Events During Follow-Up by Randomization Group f
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FIGURE 2 Total Events During Follow-Up by Randomization Group for Components
of the Primary Endpoint
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Total events were signiﬁcantly reduced with ezetimibe/simvastatin versus placebo/sim-
vastatin for the component of nonfatal MI (RR: 0.87; 95% CI: 0.79 to 0.96; p ¼ 0.004)
and nonfatal stroke (RR: 0.77; 95% CI: 0.65 to 0.93; p ¼ 0.005), and there was a
nonsigniﬁcant reduction in coronary revascularizations (RR: 0.94; 95% CI: 0.88 to 1.01;
p ¼ 0.095). There were no differences between treatment groups in total unstable angina
events or in CV deaths. CV ¼ cardiovascular; other abbreviations as in Figure 1.
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358Likewise, when we evaluated outcomes using the
PWP model, the overall PEP ﬁndings were consistent
(HR: 0.94; 95% CI: 0.90 to 0.98; p ¼ 0.002), as were
the ﬁndings with the Andersen Gill model (HR: 0.93;
95% CI: 0.88 to 0.98; p ¼ 0.01).
In an on-treatment analysis that included events
between ﬁrst dose of study drug and 30 days of
discontinuation, results were consistent with the
intent to treat analysis, with a reduction in the total
number of PEP events in the ezetimibe/simvastatin
group compared with the placebo/simvastatin group
(n ¼ 3,246 vs. n ¼ 3,539, respectively; RR: 0.89;
95% CI: 0.82 to 0.96; p ¼ 0.003).
DISCUSSION
CLINICAL BENEFIT BEYOND THE FIRST EVENT. Pre-
vious trials have consistently demonstrated a reduc-
tion in ﬁrst and total cardiovascular events associated
with more aggressive lipid lowering with intensive
statin therapy compared with moderate-dose statin
among post-ACS patients (9–16). Although lower
LDL-C levels are attributed as the principal basis of
the beneﬁt, it was not known if additional persistent
reductions in LDL-C with a nonstatin agent could
further prevent recurrent cardiovascular events.
Several previously studied lipid modifying nonstatin
agents, when added to background statin, did not
show a reduction in clinical outcomes, such as niacinor the Primary and 3 Pre-Speciﬁed Secondary Endpoints
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FIGURE 4 Primary Endpoint by Randomization Group as Assessed Using the Wei, Lin,
Weissfeld Model
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Primary endpoint events were reduced with ezetimibe/simvastatin compared with placebo/
simvastatin (HR: 0.93; 95% CI: 0.89 to 0.99; p ¼ 0.01).
FIGURE 5 Risk Differences for 100 Patients Treated for 10 Years With Ezetimibe/
Simvastatin for the Components of the Primary Endpoint
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For every 100 patients treated for 10 years, 11 total primary endpoint events were pre-
vented with ezetimibe plus simvastatin. Abbreviations as in Figure 1.
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359(17,18), torcetrapib (19), and dalcetrapib (20). The
IMPROVE-IT trial demonstrated that the addition
of the nonstatin lipid-lowering agent ezetimibe
when added to simvastatin reduced LDL-C by
approximately an additional 24% and resulted in a
signiﬁcantly lower risk of ﬁrst cardiovascular events
compared with statin monotherapy (3). The present
study extends these ﬁndings, demonstrating a
reduction in not only ﬁrst events but in total events
over long-term follow-up with the addition of ezeti-
mibe to statin therapy. Trials are currently underway
studying other nonstatin therapies for LDL-C reduc-
tion, including PCSK9 inhibitors, which will also be
evaluating clinical event reduction with greater
LDL-C lowering (FOURIER trial, NCT01764633; and
the ODYSSEY Outcomes trial, NCT01663402).
Although there were reductions in the total primary
and 3 pre-speciﬁed secondary endpoints of the trial, it
should be noted that much of the reduction associated
with the ezetimibe/simvastatin combination was
driven by the clinically important endpoints of MI and
stroke. Speciﬁcally, the reduction was greatest for
ischemic stroke. Although there was no mortality
effect in IMPROVE-IT, additional ischemic events of
stroke and MI have been associated with not only a
higher mortality, but also an impaired quality of life
(21) and higher costs (22), making these events espe-
cially critical for patients, clinicians, and the health
care system. Multiple events in a subject consume
more resources as a result of additional hospitaliza-
tions, tests, and physician visits. Health economic
analyses relating to IMPROVE-IT are underway.
LONG-TERM FOLLOW-UP. The IMPROVE-IT study
had a particularly long duration of follow-up among
post-ACS trials, with a median 6-year follow-up. This
resulted in 13% of the 18,144 subjects having more
than 1 occurrence of the primary composite endpoint,
making this trial particularly well suited to evaluate
total events. The ﬁrst event contributed 5,314 (56%)
of all events; thus 4,231 (44%) events were not
analyzed in the initial primary analysis of the trial (3)
when performing traditional Cox survival analysis of
time to ﬁrst event.
STATISTICAL CHALLENGES FOR ANALYSIS AND
STUDY LIMITATIONS. Examining efﬁcacy using total
events can present statistical challenges for anal-
ysis. Standard survival analysis methods require the
assumption of independence of failure times.
However, with total events analysis, failure times
are often correlated within a subject. The present
analysis used a negative binomial model, which
evaluates the number of occurrences of an event
over a period of time. In addition, a marginal modelwas used for analysis as described by the WLW
method (7). This technique uses survival methods
that consider the occurrence of each event sepa-
rately from the time of randomization without
speciﬁcally considering the occurrence of the ﬁrst
event or the order of events, but does take into
account the correlation between observations
within each subject. Other statistical methods
include the use of conditional models, in which
each additional event is conditional on having had
a prior event. An example of a conditional model
includes the PWP (8). With the PWP model, it is
assumed that a subject is not at risk of a second
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Among survivors of acute coronary syndromes, lipid-
lowering therapy combined with the nonstatin agent
ezetimibe plus simvastatin signiﬁcantly reduced the
total number of cardiovascular events (both ﬁrst and
subsequent) during follow-up compared with simva-
statin alone.
TRANSITIONAL OUTLOOK: Additional trials of
other intensive lipid-lowering strategies should
compare the effects on total cardiovascular events
during long-term therapy in high-risk patient
populations.
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360event until the ﬁrst event has occurred. Other novel
methods for analyzing additional events including
the win ratio (23) and weighted composite endpoints
(24). As demonstrated by Bakal et al. (25), model
selection can impact the results and conclusion of
events analysis (25). In the present analysis, the
results from both the WLW (7), Andersen Gill, and
PWP (8) models were consistent with the main
negative binomial analysis, showing a reduction in
PEP events with ezetimibe/simvastatin compared
with placebo/simvastatin.
Several limitations of total events analyses must be
acknowledged. Recurrent events within patients are
often correlated and thus may violate the assumption
of independence of events. In addition, after a ﬁrst
nonfatal event, many subjects discontinue blinded
study drug, which may result in a higher proportion
of subsequent events occurring off study drug. To
address this limitation, an on-treatment analysis was
performed which showed ﬁndings consistent with the
intent to treat analysis. Although some components
of the PEP can occur multiple times, the component
of CV death precludes the occurrence of subsequent
events. This is particularly critical when there is an
imbalance between treatment arms in the number of
CV deaths. In the present study, the number of CV
deaths was nearly identical between randomization
groups (n ¼ 537 for ezetimibe/simvastatin and n ¼ 538
for placebo/simvastatin). Given the balanced number
of CV deaths, we did not incorporate additional
modiﬁcations in our analysis.
CONCLUSIONS
Lipid-lowering therapy with ezetimibe plus simva-
statin improved clinical efﬁcacy with reductions in
total PEP events compared with simvastatin alone.
Translated into a risk difference, for every 100 pa-
tients treated for 10 years, 11 total PEP events wereprevented with ezetimibe plus simvastatin (Figure 5).
As there were no differences in cardiovascular
death or unstable angina, these 11 total events
prevented were due to a reduction of 5 MIs, 2
strokes, and 4 revascularizations. Evaluating total
events more than doubled the number of events
prevented compared with examining only the ﬁrst
event (ﬁrst PEP [n ¼ 170] vs. total PEPs [n ¼ 421])
(Central Illustration). These data provide further
support for the beneﬁt of continuation of intensive
combination lipid-lowering therapy after a recurrent
cardiovascular event.
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